Jan-Hendrik Bernhard Hardenberg

Jan-Hendrik Bernhard Hardenberg

Auto-generated profile, based on publicly available information

Jan-Hendrik Bernhard Hardenberg

Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Genome Medicine
Verified
Journal Article
Open access
PDF file
CHChristian Hinze
Christian Hinze
CKChristine Kocks
Christine Kocks
JLJanna Leiz
Janna Leiz
NKNikos Karaiskos
Nikos Karaiskos
ABAnastasiya Boltengagen
Anastasiya Boltengagen
KSKai M. Schmidt-Ott
Kai M. Schmidt-Ott
Background: Acute kidney injury (AKI) occurs frequently in critically ill patients and is associated with adverse outcomes. Cellular mechanisms underlying AKI and kidney cell responses to injury remain incompletely understood. Methods: We performed single-nuclei transcriptomics, bulk transcriptomics, molecular imaging studies, and conventional histology on kidney tissues from 8 individuals with severe AKI (stage 2 or 3 according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria). Specimens were obtained within 1–2 h after individuals had succumbed to critical illness associated with respiratory infections, with 4 of 8 individuals diagnosed with COVID-19. Control kidney tissues were obtained post-mortem or after nephrectomy from individuals without AKI. Results: High-depth single cell-resolved gene expression data of human kidneys affected by AKI revealed enrichment of novel injury-associated cell states within the major cell types of the tubular epithelium, in particular in proximal tubules, thick ascending limbs, and distal convoluted tubules. Four distinct, hierarchically interconnected injured cell states were distinguishable and characterized by transcriptome patterns associated with oxidative stress, hypoxia, interferon response, and epithelial-to-mesenchymal transition, respectively. Transcriptome differences between individuals with AKI were driven primarily by the cell type-specific abundance of these four injury subtypes rather than by private molecular responses. AKI-associated changes in gene expression between individuals with and without COVID-19 were similar. Conclusions: The study provides an extensive resource of the cell type-specific transcriptomic responses associated with critical illness-associated AKI in humans, highlighting recurrent disease-associated signatures and inter-individual heterogeneity. Personalized molecular disease assessment in human AKI may foster the development of tailored therapies.

14 July 2020 in Acta Physiologica
Verified
Journal Article
Open access
PDF file
JHJan‐Hendrik B. Hardenberg
Jan‐Hendrik B. Hardenberg
FLFriedrich C. Luft
Friedrich C. Luft
We are confronted with the most dramatic pandemic world‐wide for the past 100 years. We are armed “to‐the‐teeth” compared to 1918, we know the agent, the genomic sequence, the bodily entry, the proliferation rate, the damage pathogenesis, and the very nature of our enemy. We can identify its bodily presence and our resistance to it in terms of neutralizing antibody production. Nonetheless, the disease has laid lame the great nations of the current world and crippled the less fortunate countries. The primary disease features are not the kidney. However, the entry point has much to do with renal and cardiovascular disease. The kidney is a common target of corona‐virus (SARS‐CoV2) disease; the longer‐term consequences could be as well.

1 November 2024 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
JHJan-Hendrik B Hardenberg
Jan-Hendrik B Hardenberg
JKJulius Valentin Kunz
Julius Valentin Kunz
KRKerstin Rubarth
Kerstin Rubarth
MMMirja Mittermaier
Mirja Mittermaier
MPMareen Pigorsch
Mareen Pigorsch
PEPhilipp Enghard
Philipp Enghard
Hypernatremia presents a common complication in ICU patients, associated with increased mortality and length of stay. This study investigates the effect of sodium chloride 0.9% compared with glucose 5% solution as the standard intravenous drug diluent on the prevalence of hypernatremia in a medical ICU. This is a retrospective before-and-after study comparing two consecutive patient groups before- and after the standard drug solvent was changed from sodium chloride 0.9% to glucose 5% solution for compatible medications. A total of 265 adult COVID-19 patients admitted between October 2020 and March 2021 to the study intensive care unit were included, with 161 patients in the timeframe when sodium chloride 0.9% was employed as the standard drug solvent and 104 patients when glucose 5% was used. Routine sodium measurements from arterial and venous blood gases, along with heparinized lithium plasma, were analyzed. The daily sodium concentrations and the prevalence of severe hypernatremia (>150 mmol/l) were assessed during the first 8 days after ICU admission. Baseline characteristics were similar between the two groups. The cumulative volume of intravenous drug diluents was comparable. In the glucose 5% group, about half of the total drug diluent volume was glucose 5% (mean [SD]: 2251.6 [2355.4] mL), compared to 135.0 [746.9] mL (p < 0.001) in the control group. Average sodium concentrations diverged after day two, with the glucose 5% group consistently showing lower sodium levels (mean difference of approximately 2.5 mmol/L). Severe hypernatremia occurred less frequently in the glucose 5% group (6.6% vs. 20%). Glucose 5% solution as the standard intravenous drug solvent significantly reduced sodium concentrations and the occurrence of severe hypernatremia. This simple modification in solvent choice may serve as a preventive strategy against hypernatremia in the ICU. Further prospective research is necessary to determine associated clinical outcomes. Trial registration: The trial was registered in the German Clinical Trials Register (DRKS00031877).

29 June 2022 in Dermatopathology
Verified
Journal Article
Open access
PDF file
MUMirjana Urosevic-Maiwald
Mirjana Urosevic-Maiwald
JHJan-Hendrik B. Hardenberg
Jan-Hendrik B. Hardenberg
JHJürg Hafner
Jürg Hafner
Marie-Charlotte BrüggenMarie-Charlotte Brüggen
Marie-Charlotte Brüggen
The use of levamisole as the most frequent adulterant of cocaine has merged in previously unknown toxicities, notably a disease entity called cocaine/levamisole-associated autoimmune syndrome (CLAAS). Clinically, CLAAS can manifest with diverse cutaneous and extracutaneous features sharing common laboratory findings (neutropenia, autoantibody patterns). We report the case of a cocaine-abusing female patient with relapsing episodes of painful ulcers, worsening and expanding over a three-year period. The case exhibited all features of a drug-induced, skin-limited, ANCA-associated vasculitis, evolving over time to PG-like findings. In both disease stages, the patient responded well to the cessation of cocaine exposure and systemic glucocorticosteroids. This case demonstrates the continuous nature of cutaneous CLAAS manifestations in a single patient. CLAAS has become a major public health issue in the at-risk group of cocaine users, and clinicians should be alert of this condition when treating cocaine users presenting with single or multiple skin ulcerations.

27 May 2024 in Scientific Reports
Verified
Journal Article
Open access
SAStefan Angermair
Stefan Angermair
JHJan-Hendrik Hardenberg
Jan-Hendrik Hardenberg
KRKerstin Rubarth
Kerstin Rubarth
FBFelix Balzer
Felix Balzer
NANilufar Akbari
Nilufar Akbari
STSascha Treskatsch
Sascha Treskatsch
The COVID-19 pandemic has posed a major challenge to healthcare systems globally. Millions of people have been infected, and millions of deaths have been reported worldwide. Glucocorticoids have attracted worldwide attention for their potential efficacy in the treatment of COVID-19. Various glucocorticoids with different dosages and treatment durations have been studied in patients with different severities, with a suitable dosage and treatment duration not yet defined. This study aimed to investigate whether in-hospital survival differs between critically ill patients treated with low-dose glucocorticoids, high-dose glucocorticoids or no glucocorticoids. All critically ill patients admitted to the intensive care unit of the Charité Hospital—Universitätsmedizin Berlin between February 2020 and December 2021 with COVID-19 pneumonia receiving supplemental oxygen were eligible to participate in this multicenter real-world data study. Patients were retrospectively assigned to one of three groups: the high corticosteroid dose (HighC) group (receiving 6 mg parenteral dexamethasone or an equivalent corticosteroid dosage for ten days), the low corticosteroid dose (LowC) group (receiving less than 6 mg parenteral dexamethasone or an equivalent corticosteroid dosage for ten days), or the no corticosteroid (NoC) group. Overall survival and risk effects were compared among groups within the total observation period, as well as at 35 days after the onset of COVID-19 symptoms. Adjusted multivariable Cox proportional hazard regression analysis was performed to compare the risk of death between the treatment groups. Out of 1561 critically ill COVID-19 patients, 1014 were included in the baseline analysis. In the survival study, 1009 patients were assigned to the NoC (n = 346), HighC (n = 552), or LowC group (n = 111). The baseline characteristics were balanced between groups, except for age, BMI, APACHE II score, SOFA and SAPS II. While the 35-day survival did not show any differences, a landmark analysis of the patients surviving beyond 35 days revealed differences between groups. The restricted mean survival time was 112 days in the LowC group [95% CI: 97 – 128], 133 days in the HighC group [95% CI: 124 – 141] and 144 days in the NoC group [95% CI: 121 – 167]. The multivariable-adjusted Cox proportional hazard analysis indicated that, regardless of age, sex, health status or invasive oxygenation, a low-dose treatment increased the hazard of death of critically ill COVID-19 patients by a factor of 2.09 ([95% CI: 0.99, 4.4], p = 0.05) and a high-dose corticosteroid treatment increased the risk by a factor of 1.07 ([95% CI: 0.53, 2.15], p = 0.85) compared to no treatment with glucocorticoids. The analysis reveals that corticosteroid treatment does not influence the survival of critically ill COVID-19 patients in the intensive care unit within 35 days. Our evaluations further suggest that regardless of ventilation status, the decision-making process for administering corticosteroid therapy should account for the individual severity of the illness.

1 January 2021 in Der Nephrologe
Verified
Journal Article
Closed access
PDF file
JHJan-Hendrik B. Hardenberg
Jan-Hendrik B. Hardenberg
HSHelena Stockmann
Helena Stockmann
KEKai-Uwe Eckardt
Kai-Uwe Eckardt
KSKai M. Schmidt-Ott
Kai M. Schmidt-Ott